BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 34321320)

  • 1. PARIS farnesylation prevents neurodegeneration in models of Parkinson's disease.
    Jo A; Lee Y; Kam TI; Kang SU; Neifert S; Karuppagounder SS; Khang R; Kang H; Park H; Chou SC; Oh S; Jiang H; Swing DA; Ham S; Pirooznia S; Umanah GKE; Mao X; Kumar M; Ko HS; Kang HC; Lee BD; Lee YI; Andrabi SA; Park CH; Lee JY; Kim H; Kim H; Kim H; Cho JW; Paek SH; Na CH; Tessarollo L; Dawson VL; Dawson TM; Shin JH
    Sci Transl Med; 2021 Jul; 13(604):. PubMed ID: 34321320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. S-nitrosylated PARIS Leads to the Sequestration of PGC-1α into Insoluble Deposits in Parkinson's Disease Model.
    Kim H; Lee JY; Park SJ; Kwag E; Kim J; Shin JH
    Cells; 2022 Nov; 11(22):. PubMed ID: 36429110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson's disease.
    Shin JH; Ko HS; Kang H; Lee Y; Lee YI; Pletinkova O; Troconso JC; Dawson VL; Dawson TM
    Cell; 2011 Mar; 144(5):689-702. PubMed ID: 21376232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PINK1 Primes Parkin-Mediated Ubiquitination of PARIS in Dopaminergic Neuronal Survival.
    Lee Y; Stevens DA; Kang SU; Jiang H; Lee YI; Ko HS; Scarffe LA; Umanah GE; Kang H; Ham S; Kam TI; Allen K; Brahmachari S; Kim JW; Neifert S; Yun SP; Fiesel FC; Springer W; Dawson VL; Shin JH; Dawson TM
    Cell Rep; 2017 Jan; 18(4):918-932. PubMed ID: 28122242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repression of rRNA transcription by PARIS contributes to Parkinson's disease.
    Kang H; Shin JH
    Neurobiol Dis; 2015 Jan; 73():220-8. PubMed ID: 25315684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Farnesol prevents aging-related muscle weakness in mice through enhanced farnesylation of Parkin-interacting substrate.
    Bae JH; Jo A; Cho SC; Lee YI; Kam TI; You CL; Jeong HJ; Kim H; Jeong MH; Jeong Y; Ha YW; Kim YS; Kim J; Woo SH; Kim MS; Shin ES; Song SO; Kang H; Khang R; Park S; Park J; Dawson VL; Dawson TM; Park SC; Shin JH; Kang JS
    Sci Transl Med; 2023 Aug; 15(711):eabh3489. PubMed ID: 37647389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promotion of mitochondrial biogenesis via the regulation of PARIS and PGC-1α by parkin as a mechanism of neuroprotection by carnosic acid.
    Lin CY; Huang YN; Fu RH; Liao YH; Kuo TY; Tsai CW
    Phytomedicine; 2021 Jan; 80():153369. PubMed ID: 33070082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detrimental effects of oxidative losses in parkin activity in a model of sporadic Parkinson's disease are attenuated by restoration of PGC1alpha.
    Siddiqui A; Rane A; Rajagopalan S; Chinta SJ; Andersen JK
    Neurobiol Dis; 2016 Sep; 93():115-20. PubMed ID: 27185595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysregulation of parkin in the substantia nigra of db/db and high-fat diet mice.
    Khang R; Park C; Shin JH
    Neuroscience; 2015 May; 294():182-92. PubMed ID: 25779963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PARIS induced defects in mitochondrial biogenesis drive dopamine neuron loss under conditions of parkin or PINK1 deficiency.
    Pirooznia SK; Yuan C; Khan MR; Karuppagounder SS; Wang L; Xiong Y; Kang SU; Lee Y; Dawson VL; Dawson TM
    Mol Neurodegener; 2020 Mar; 15(1):17. PubMed ID: 32138754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parkin interacting substrate phosphorylation by c-Abl drives dopaminergic neurodegeneration.
    Kim H; Shin JY; Jo A; Kim JH; Park S; Choi JY; Kang HC; Dawson VL; Dawson TM; Shin JH; Lee Y
    Brain; 2021 Dec; 144(12):3674-3691. PubMed ID: 34581802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of transketolase as a target of PARIS in substantia nigra.
    Kim H; Kang H; Lee Y; Park CH; Jo A; Khang R; Shin JH
    Biochem Biophys Res Commun; 2017 Nov; 493(2):1050-1056. PubMed ID: 28939041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parkin loss leads to PARIS-dependent declines in mitochondrial mass and respiration.
    Stevens DA; Lee Y; Kang HC; Lee BD; Lee YI; Bower A; Jiang H; Kang SU; Andrabi SA; Dawson VL; Shin JH; Dawson TM
    Proc Natl Acad Sci U S A; 2015 Sep; 112(37):11696-701. PubMed ID: 26324925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decoding the Parkinson's Symphony: PARIS, Maestro of Transcriptional Regulation and Metal Coordination for Dopamine Release.
    Hwang Y; Mohammad Mydul Islam AK; Park S; Kang HG; Lee C; Lim MH; Lee SJ
    ACS Chem Neurosci; 2024 Feb; 15(3):447-455. PubMed ID: 38241020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PGC-1α Promoter Methylation in Parkinson's Disease.
    Su X; Chu Y; Kordower JH; Li B; Cao H; Huang L; Nishida M; Song L; Wang D; Federoff HJ
    PLoS One; 2015; 10(8):e0134087. PubMed ID: 26317511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuronal NLRP3 is a parkin substrate that drives neurodegeneration in Parkinson's disease.
    Panicker N; Kam TI; Wang H; Neifert S; Chou SC; Kumar M; Brahmachari S; Jhaldiyal A; Hinkle JT; Akkentli F; Mao X; Xu E; Karuppagounder SS; Hsu ET; Kang SU; Pletnikova O; Troncoso J; Dawson VL; Dawson TM
    Neuron; 2022 Aug; 110(15):2422-2437.e9. PubMed ID: 35654037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrative genome-wide analysis of dopaminergic neuron-specific PARIS expression in Drosophila dissects recognition of multiple PPAR-γ associated gene regulation.
    Yazar V; Kang SU; Ha S; Dawson VL; Dawson TM
    Sci Rep; 2021 Nov; 11(1):21500. PubMed ID: 34728675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defects in Mitochondrial Biogenesis Drive Mitochondrial Alterations in PARKIN-Deficient Human Dopamine Neurons.
    Kumar M; Acevedo-Cintrón J; Jhaldiyal A; Wang H; Andrabi SA; Eacker S; Karuppagounder SS; Brahmachari S; Chen R; Kim H; Ko HS; Dawson VL; Dawson TM
    Stem Cell Reports; 2020 Sep; 15(3):629-645. PubMed ID: 32795422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of the ATF2/CREB-PGC-1α pathway by metformin leads to dopaminergic neuroprotection.
    Kang H; Khang R; Ham S; Jeong GR; Kim H; Jo M; Lee BD; Lee YI; Jo A; Park C; Kim H; Seo J; Paek SH; Lee YS; Choi JY; Lee Y; Shin JH
    Oncotarget; 2017 Jul; 8(30):48603-48618. PubMed ID: 28611284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. REST Protects Dopaminergic Neurons from Mitochondrial and α-Synuclein Oligomer Pathology in an Alpha Synuclein Overexpressing BAC-Transgenic Mouse Model.
    Ryan BJ; Bengoa-Vergniory N; Williamson M; Kirkiz E; Roberts R; Corda G; Sloan M; Saqlain S; Cherubini M; Poppinga J; Bogtofte H; Cioroch M; Hester S; Wade-Martins R
    J Neurosci; 2021 Apr; 41(16):3731-3746. PubMed ID: 33563726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.